Sinovac Biotech (SVA) director Lo Yuk Lam reports 90,000 shares on Form 3

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD director Lo Yuk Lam filed an initial statement of beneficial ownership on Form 3. The filing reports direct ownership of 90,000 common shares, par value $0.001 per share. This is a holdings report only and does not reflect any recent share purchase or sale.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LO YUK LAM

(Last) (First) (Middle)

10/F, 20 BUTE STREET

MONGKOK, KOWLOON

(Street)

HONG KONG

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	90,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SINOVAC BIOTECH (SVA) Form 3 for Lo Yuk Lam report?

The Form 3 reports director Lo Yuk Lam’s initial beneficial ownership in SINOVAC BIOTECH. It shows his directly held common shares at the time he became a reporting insider, without indicating any recent trade activity.

How many SINOVAC BIOTECH (SVA) shares does Lo Yuk Lam hold on this Form 3?

Lo Yuk Lam is reported as holding 90,000 common shares of SINOVAC BIOTECH. These are common shares with a par value of $0.001 per share, listed as his position following the reported holdings entry.

Does the SINOVAC BIOTECH (SVA) Form 3 show Lo Yuk Lam buying or selling shares?

The Form 3 does not show a buy or sell transaction. It records his status as a beneficial owner with 90,000 directly held common shares, serving as a baseline disclosure rather than a trading report.

Is Lo Yuk Lam’s ownership in SINOVAC BIOTECH (SVA) direct or indirect?

The filing classifies his 90,000 common shares as direct ownership. The ownership code is listed as “D,” meaning the shares are held directly in his name rather than through an intermediary entity.

What is the purpose of this SINOVAC BIOTECH (SVA) Form 3 filing?

This Form 3 serves as an initial beneficial ownership statement for director Lo Yuk Lam. It establishes his starting share position in SINOVAC BIOTECH for public disclosure when he became subject to insider reporting rules.